• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
NTRA

NTRA

Natera, Inc.

NASDAQHealthcareMedical - Diagnostics & ResearchUS

USD211.85

-0.88 (-0.41%)

Rating:C-

Company Profile

CEO

Steven Leonard Chapman

IPO Date

2015-07-01

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Exchange

NASDAQ

Country

US

Market Metrics

Open

$209.96

Prev. Close

$212.73

Day Low

$204.16

Day High

$213.26

52W Low

$131.81

52W High

$256.36

Market Cap

$30.34B

Volume

1.46M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

47.2%

Avg Negative

1.3%

Avg Neutral

51.6%

News Feed

Natera Announces Second Quarter 2021 Earnings Conference Call

PRNewsWire·7/29/2021·↑ positive

New Publication Shows 96% Overall Survival Among Metastatic Colorectal Cancer Patients Who Test MRD-Negative with Signatera® After Surgery

PRNewsWire·7/22/2021·↑ positive

Natera Announces Pricing of Follow-On Offering

PRNewsWire·7/22/2021·
↑ positive

Natera Launches Proposed Follow-On Offering

PRNewsWire·7/20/2021·↑ positive

Natera Reports Preliminary Second Quarter 2021 Results

PRNewsWire·7/19/2021·↑ positive

New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical Utility of the Signatera® MRD Test in Colorectal Cancer

PRNewsWire·7/2/2021·↑ positive

Natera: Leading cfDNA Diagnostics Company Offers Strong Growth And Fair Trading Value

Seeking Alpha·7/1/2021·↑ positive

Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China

PRNewsWire·6/24/2021·↑ positive

How Natera Is Defending Its Lead in a $15B Cancer-Testing Market

Barrons·6/22/2021·↑ positive

Natera Awarded Advanced Diagnostic Laboratory Test (ADLT) Status for its Signatera® MRD Test From CMS

PRNewsWire·6/18/2021·↑ positive